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Received 5 June 2009; received in revised form 1 August 2009; accepted 18 August 2009Abstract The potential of pluripotent human cells, such as human embryonic stem cells (hESCs)
and induced pluripotent stem (iPS) cells, to differentiate into any adult cell type makes them ideally suited for the generation of
various somatic cells and tissues in vitro. This remarkable differentiation capacity permits analyzing aspects of human embryonic
development in the laboratory, as well as generating specialized adult human cells for screening drugs, and for replacing tissues
damaged by injury or degenerative diseases, such as diabetes. Understanding and controlling the fundamental processes that drive
the differentiation of specialized cells are the keys to the eventual application of this technology to patients. In this review, we
discuss the different protocols developed that are aimed at deriving β-cells from hESCs. Despite many differences, successful
strategies share a general adherence to the normal differentiation pathway through definitive endoderm. Mimicking normal
pancreagenesis offers the best strategy for producing glucose-responsive insulin-producing cells in vitro for people with diabetes.
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Diabetes mellitus is a metabolic disorder characterized by
elevated blood glucose levels. It can lead acutely to
ketoacidosis or nonketotic hyperosmolar coma, and long-
term to chronic complications, including cardiovascular
disease, stroke, amputation, and microvascular damage to
retina, kidney, and nerves. Cellular uptake of glucose from
the blood is regulated principally by the hormone insulin.
The pancreatic β-cells produce insulin as a pro-hormone that
is cleaved into mature hormone plus C-peptide inside storage
granules prior to secretion, which is regulated by extracel-
lular stimuli, especially glucose. Together with other
endocrine cells, including glucagon-producing α-cells, so-
matostatin-producing δ-cells, and pancreatic polypeptide-
producing PP-cells, β-cells form the scattered islets of
Langerhans, which compose 1–2% of the pancreas.
Of the two major forms of diabetes mellitus, type 1
results from a complete loss of insulin due to T-cell-mediated
autoimmune destruction of the β-cells, and type 2 results
from relative insulin deficiency due to inadequate insulin
secretion in the setting of reduced insulin sensitivity. Some
patients with type 2 diabetes can achieve normal blood
glucose levels by combining lifestyle modifications with oral
insulin secretagogues and sensitizers. In contrast, many
people with type 2 diabetes and all with type 1 diabetes
require insulin replacement, usually via injection. The
impossibility of perfectly matching insulin replacement to
the rapidly fluctuating demands causes the complications
of diabetes.
Currently, transplantation of whole pancreas or purified
islets from cadaveric donors offers the only cure for pa-
tients that require insulin therapy (White et al., 2009).
However, preventing rejection of the allograft requires
permanent treatment with immunosuppressive drugs with
multiple adverse side-effects. Furthermore, at best, cada-
veric tissue can provide sufficient β-cell mass for only a
minute fraction of the patients that could benefit from
β-cell replacement.
The ability of embryonic stem cells (ESCs) to divide
indefinitely, combined with their potential to differentiate
into any of the N200 different types of cells of adult
mammals (Keller, 2005), suggests a possible solution to the
supply problem. Only induced pluripotent stem (iPS) cells
(Takahashi and Yamanaka, 2006; Takahashi et al., 2007; Yu
et al., 2007) rival the expansion and differentiation capacity
of ESCs. Their genetic modification makes iPS cells
unsuitable for clinical applications, although this problem
can be solved by modifying the methods for their derivation
(Kaji et al., 2009; Yu et al., 2009; Zhou et al., 2009; Kim
et al., 2009). In this review, we will focus specifically on
reports describing the generation of insulin-producing cells
from human ESCs (hESCs) that might eventually provide
cell-based therapies to restore the β-cell mass in people
with diabetes.Pancreas development
Lessons from the mouse: Formation of endoderm
In order to derive β-cells from hESCs in vitro, we must first
understand the fundamental processes that underlie devel-
opment of the pancreas in vivo, starting at the stage from
which ESCs are derived (Fig. 1). Most of our knowledge of
pancreatic development comes from studies in model
organisms: mouse, chicken, zebrafish, and Xenopus. Despite
obvious differences in scale, development of the pancreas is
highly conserved among these vertebrates.
Within ∼4 days after fertilization, the mouse egg
develops into a blastocyst, comprising an outer shell of
∼100 trophoblast cells encasing a compact group of ∼25
inner cell mass (ICM) cells clustered on one side of the cavity
(Theiler, 1989). From these ICM cells, all of the various
tissues of the adult animal will eventually develop. ICM cells
express several pluripotency-associated transcription fac-
tors, including the three key factors Oct4 (Niwa et al., 2000),
Sox2 (Yuan et al., 1995; Avilion et al., 2003), and Nanog
(Mitsui et al., 2003; Chambers et al., 2003), which act
cooperatively (Boyer et al., 2005). Embryonic stem cells are
derived from the ICM cells, and retain both their self-renewal
capacity and their pluripotency.
Around embryonic day 4.5 (e4.5), the blastocyst implants
into the uterine epithelium and enlarges considerably. At the
same time, the ICM develops into the epiblast and a layer of
primitive endoderm that covers the blastocoelic side of this
epiblast (for review, see (Rossant, 2004)). Eventually, the
primitive endoderm will produce extraembryonic lineages,
whereas the embryonic ectoderm will give rise to all defi-
nitive tissues of the embryo.
At ∼e5.5, the ectoplacental cone sprouts from the
polar trophectoderm to invade the maternal tissue. Inter-
nally, cells from the trophectoderm and embryonic ecto-
derm divide rapidly and produce the proamniotic cavity,
thus forming the egg cylinder. The outside of this egg
cylinder and the inside of the trophectoderm are covered
by a layer of visceral endoderm and parietal endoderm,
respectively, both of which are derived from the primitive
endoderm (Theiler, 1989). At the end of this stage, the
embryonic ectoderm and extraembryonic ectoderm are
morphologically distinct, and a longitudinal axis that es-
tablishes left-right symmetry becomes evident from the
appearance of the primitive streak at the posterior end of
the embryo (for review, see (Rossant and Tam, 2004)).
Formation of this primitive streak is preceded by local acti-
vity of Brachyury T and Wnt3 (Rivera-Pérez and Magnuson,
2005).
Gastrulation, which starts at ∼e6.5, divides the embry-
onic ectoderm of the epiblast into the three primary germ
layers: ectoderm, endoderm, and mesoderm. The latter two
layers originate from a common cluster of mesendoderm
cells that aggregate at the anterior primitive streak region
Figure 1 (A) Schematic overview of pancreas development, and the transcription factors involved in this process during mouse
embryogenesis. Developmental stages are indicated as embryonic day for mouse (black) and week of development for human (gray);
note that the human developmental stage is an approximation. (B) Derivation of endocrine cells from a common precursor. The
intermediate developmental stages are marked by the timely expression of pancreas-associated transcription factors.
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streak and then move laterally and anteriorly to develop into
mesoderm and endoderm, respectively, thus displacing thevisceral endoderm to extraembryonic sites (Tam et al., 2007)
(for reviews, see (Tam et al., 1993; Wells and Melton, 1999).
Canonical Wnt signaling contributes to the establishment of
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mesendoderm cells (Liu et al., 1999). Nodal secretion from
the node governs the decision to become mesoderm versus
endoderm: low levels of Nodal induce differentiation into
mesoderm, and high levels drive differentiation into endo-
derm (Conlon et al., 1994; Brennan et al., 2001). Exogenous
Activin A can mimic the endoderm fate decision by binding to
the same receptors as Nodal (De Caestecker, 2001).
Definitive endoderm is marked by a transient upregula-
tion of Brachyury T (Kubo et al., 2004), and expression of Gsc
(Blum et al., 1992), Foxa2 (Sasaki and Hogan, 1993;
Monaghan et al., 1993), Gata5 (Weber et al., 2000; Reiter
et al., 2001), and Sox17 (Kanai-Azuma et al., 2002) as well as
the primitive streak marker Mixl1 (Pearce and Evans, 1999;
Hart et al., 2002). Visceral endoderm also expresses
Brachyury T, Gsc, Foxa2, and Sox17 (Wilkinson et al.,
1990), but it can be distinguished from definitive endoderm
by its expression of Sox7 (Kanai-Azuma et al., 2002) and Mox1
and 2 (Candia et al., 1996). Recently, it has been shown that
the chemokine Cxcl12b and its receptor Cxcr4a restrict the
anterior migration of the endoderm in zebrafish (Nair and
Schilling, 2008).Lessons from the mouse: Development of the
pancreas from endoderm
After initial anterior–posterior patterning has occurred, and
gastrulation has completed at ∼e7.5, the definitive endo-
derm begins to roll up to form the gut tube, while regionally
distinct gene expression patterns emerge along the gut
endoderm (for review, see (Wells and Melton, 1999)) in a
process involving BMPs (Winnier et al., 1995; Solloway and
Robertson, 1999), Gata4 (Narita et al., 1997), Furin
(Roebroek et al., 1998), and matrix metallopeptidase 2
(Linask et al., 2005). Cells within the endoderm in the region
that will become the foregut/midgut junction are specified
to become pancreas as early as e8.0, and the expression of
patterning genes such as the transcription factors Pdx1,
Ptf1a, Hnf1b, Hhex, Foxa2, Mnx1 (Hlxb9), and Onecut1
(Hnf6a) initiate around this time (for reviews, see (Jensen,
2004; Murtaugh, 2007; Jørgensen et al., 2007)). Retinoic
acid-mediated signaling plays a critical role in this patterning
of the foregut and prospective pancreatic domain (Kumar et
al., 2003), and acts upstream of key transcription factors
such as Pdx1, which is crucial for pancreas development
(Jonsson et al., 1994; Offield et al., 1996). Notably, while
these transcription factors are critical for the patterning and
eventual development and function of the pancreas, none
are absolutely restricted to cells of the pancreatic lineage,
or even endoderm.
At embryonic day 9.5, the first morphological evidence of
the pancreas appears as a thickening on the dorsal side of the
gut that grows into the dorsal pancreatic bud, followed by
the two ventral/lateral buds a day later, one of which
dominates and eventually fuses with the dorsal bud. Distinct
signaling events guide dorsal and ventral bud development,
although suppression of hedgehog signaling plays an impor-
tant role in both. Initially, Shh expression extends through-
out the anterior–posterior axis of the developing gut tube
endoderm, but is repressed specifically in the dorsal and
ventral pancreatic buds by notochord signaling via FGF2(basic FGF) and Activin (Hebrok et al., 1998; Kim and Melton,
1998). In contrast, FGF2 signaling from the cardiac meso-
derm induces liver-specific differentiation of the ventral
bud, which has a pancreatic fate when FGF2 is absent
(Deutsch et al., 2001).
As the buds appear, the expanding pancreatic epithelium
initiates the expression of the transcription factors Sox9,
Nkx2.2, and Nkx6.1 (Lynn et al., 2007; Seymour et al., 2007),
in addition to the gut endoderm patterning genes Pdx1,
Ptf1a, Hnf1b, Hhex, Foxa2, Mnx1, and Onecut1 noted above.
Interestingly, Mnx1 is required for the expansion of the
dorsal bud (Harrison et al., 1999; Li et al., 1999), and Hhex is
required for the ventral bud (Bort et al., 2004), while FGF10
from the overlying dorsal mesenchyme regulates the growth
of the pancreatic epithelium in both the dorsal and the
ventral pancreatic buds (Bhushan et al., 2001). Expansion of
the dorsal and ventral pancreatic buds continues, during
which the gut rotates and brings the two pancreatic
rudiments in closer proximity around e12.5. While the
connection of the dorsal part to the duodenum diminishes,
that of the ventral part will form the main duct.
Differentiation of the endocrine cells initiates slightly
earlier in the dorsal bud than in the ventral bud, with
glucagon-positive cells appearing first at ∼e9.5. Differenti-
ation of the endocrine cells requires the transient expression
of the transcription factor Ngn3, which commits individual
cells in the pancreatic epithelium to the endocrine lineage
(Apelqvist et al., 1999; Schwitzgebel et al., 2000; Gu et al.,
2002) (for review, see (Miyatsuka et al., 2008)). The broadly
expressed pancreatic epithelial transcription factors Sox9,
Hnf1b, Foxa2, and Onecut1 collaborate in activating Ngn3
expression (Lynn et al., 2007), while Notch-Delta signaling
activates the inhibitory transcription factor Hes1, thereby
inhibiting Ngn3 expression and endocrine differentiation in
the majority of the pancreatic epithelial cells (for review,
see (Oliver-Krasinski and Stoffers, 2008)).
By e10.5, insulin-positive cells can be detected in the
primitive buds, but neither these nor the early glucagon-
expressing cells noted above have characteristics of mature
β- and α-cells, respectively, nor are they precursors of
mature islet cells (Herrera, 2000; Wilson et al., 2002).
At ∼e13, a secondary transition that peaks around e14.5
initiates, during which a second wave of Ngn3 expression
occurs (Villasenor et al., 2008). Ngn3 activates the expres-
sion of a number of endocrine transcription factors including
Neurod1 (Huang et al., 2000), Pax4 (Smith et al., 2003), and
Nkx2.2 (Watada et al., 2003), the latter two of which govern
the further differentiation into β-cells. Eventually, the
combinatorial expression of multiple factors defines the
identity of the specific endocrine cells present in islets (Fig.
1) (for review, see (Spence and Wells, 2007)). Basically, α-
cells are characterized by Pax6, Nkx2.2, Irx1 and 2, Brn4, and
Arx; β-cells by Pax4, Pax6, Nkx2.2, Nkx6.1, Mnx1, MafA, and
Pdx1; δ-cells by Pax4 and Pax6; PP-cells by Nkx2.2; the
factors essential for development of ɛ-cells are yet unknown
(for reviews, see (Oliver-Krasinski and Stoffers, 2008; Spence
and Wells, 2007; Martin et al., 2007)).
The human pancreas
Due to obvious ethical constraints, knowledge about human
pancreas development is more limited andmostly descriptive
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show that, in addition to the obvious difference in duration of
pancreagenesis, some dissimilarities at the developmental,
morphological, and gene expression level (Jeon et al., 2009)
exist between the mouse and the human pancreas (for
review, see (Gittes, 2009)).
Around the fifth week of human development (5WD), the
ventral pancreatic bud migrates toward the dorsal bud and
they fuse a week later. Between 7WD and 8WD, the pancreas
consists of pyramidal cells that are in contact with loose and
dense peripancreatic mesenchyme (Polak et al., 2000). At
this stage, the first endocrine cells start to appear; many of
which are positive for insulin, glucagon, and somatostatin,
simultaneously, whereas pancreatic polypeptide-containing
cells can be detected from 9WD onward (Polak et al., 2000).
By 11WD, the percentage of polyhormonal cells has
decreased drastically, while the endocrine cell density has
enlarged considerably. As indicated by Ki-67 expression, a
marker for dividing cells, the hormone-positive cells in human
islets cease to proliferate after ∼20WD (Bouwens et al.,
1997), even though the highest increase in endocrine tissue
occurs between 21WD and 40WD (Stefan et al., 1983).
Additionally, differentiated human islets have a very limited
proliferative capacity after 12WD, suggesting that a hor-
mone-negative precursor cell population is the foremost
source for islet neogenesis (Bouwens et al., 1997).
The overall morphology of the mature pancreas differs
between humans and mice: the human pancreas forms a
single, smooth organ with a fibrous stroma, whereas the
mouse pancreas has an irregular, lobular structure of more
loosely connected tissue. In contrast to the organized mouse
islets, which are composed of a large core of β-cells
enveloped by a layer of α-cells and other endocrine cells,
primate islets contain endocrine cells that are scattered in a
more random pattern (Wieczorek et al., 1998). The human
pancreas contains approximately one million islets consisting
of a thousand endocrine cells each, ∼75% of which are β-
cells. In addition, a significant fraction of the β-cells in the
adult human pancreas are found outside of organized islets
(Butler et al., 2003).
Diabetic mice require 2000 to 3000 human islets to
establish normoglycemia (Gaber et al., 2004; Kroon et al.,
2008). However, transplantations of donor-derived islets
(White et al., 2009) have shown that the number of
functional β-cells that can be extracted from a single
cadaveric pancreas is often not enough to restore euglycemia
in a human diabetic individual. This, again, illustrates the
need for alternative sources of β-cells to treat the vast and
rising number of diabetic patients.
Differentiation of human embryonic stem cells
into pancreatic endocrine cells
Derivation, culture, and differentiation of human
embryonic stem cells
As noted above, ESCs are derived from the ICM of blastocyst-
stage embryos, and can self-renew indefinitely when grown
in serum-containing medium on mitotically inactive mouse
feeder cells, while retaining the potential to differentiate
into any adult cell type (Thomson et al., 1998; Reubinoff etal., 2000; Cowan et al., 2004). Recently, procedures have
been developed to derive and maintain hESCs on human
feeder cells as well as feeder-free matrices in various growth
factor-supplemented basal media (Rao and Zandstra, 2005;
Klimanskaya et al., 2005; Ludwig et al., 2005). In addition,
hESCs can be transferred from feeders to feeder-free
conditions and vice versa without affecting their pluripo-
tency, although such transfers do affect their protein
expression profile (Van Hoof et al., 2008). Irrespectively,
advancements like these allow the generation of clinical-
grade cell lines by omitting nonhuman components.
Spontaneous differentiation of ESCs can be induced by
growth in suspension to form aggregates (i.e., embryoid
bodies) in the absence of factors that support self-renewal.
However, individual lines show vast differences in their
propensity to differentiate into particular lineages (Osafune
et al., 2008). Numerous groups have reported the derivation
of endocrine hormone-expressing cells from spontaneously
differentiating cultures (Lavon et al., 2006; Xu et al., 2006;
Segev et al., 2004; Baharvand et al., 2006; Otonkoski et al.,
1993; Treutelaar et al., 2003; Humphrey et al., 2003;
Delacour et al., 2004; Brolén et al., 2005), but this approach
is unlikely to form a viable platform for generating sufficient
numbers of pure populations of cells for clinical use.
Lineage-specific differentiation of ESCs proved most suc-
cessful when these cells were exposed to signals mimicking
those that normally drive differentiation during embryonic
development.Lessons from mouse embryonic stem cells:
Differentiation into insulin-producing cells
The derivation of mouse ESCs (mESCs) (Evans and Kaufman,
1981; Martin, 1981) preceded that of the first hESC lines by
∼17 years (Thomson et al., 1998). Hence, the first protocols
designed to promote differentiation into insulin-secreting
cells specifically were developed for mESCs. These protocols
relied on either transfection with an expression construct
harboring an antibiotic resistance gene under control of the
insulin promoter (Soria et al., 2000), or embryoid body
formation (Shiroi et al., 2002). Insulin-producing cells were
also successfully derived from hESCs (Assady et al., 2001),
implying for the first time that hESCs can differentiate into
cells with β-cell characteristics. More specific multistage
procedures developed for the differentiation of mESCs into
neural tissues also generated cells containing islet hormones
(Lumelsky et al., 2001); (Hori et al., 2002). However, the
absence of C-peptide as well as insulin mRNA revealed that
intracellular insulin did not originate from de novo synthesis
in these cells, but from uptake from the culture media
(Rajagopal et al., 2003; Sipione et al., 2003; Hansson et al.,
2004; Paek et al., 2005a,b). In addition, most of the islet
markers used, such as the transcription factors described
above, cannot uniquely identify cells of pancreatic lineage,
because they also mark cells of other lineages, especially
neural ectoderm.
Recently, the protocol developed originally for the
differentiation of mESCs (Lumelsky et al., 2001) was
modified and applied to hESCs (Mao et al., 2009), but the
characterization of the cells generated in this study is fairly
limited. Although C-peptide-positive cells were reported to
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did not fully protect streptozotocin-treated mice from
developing diabetes; yet, their fasting blood glucose levels
approximated that of healthy animals. These findings
suggest that, even though the transplanted cells are unable
to respond adequately to hyperglycemia, they produce
sufficient insulin to decrease elevated blood glucose levels
over time.
Formation of definitive endoderm
Initially, most studies focused primarily on analyzing the
gene products expressed at the end of the differentiation
procedures. However, the intervening steps, especially the
generation of definitive endoderm, an essential step for
pancreagenesis in vivo, were not addressed. Deriving
endoderm from hESCs proved challenging, until incubation
with Activin A (De Caestecker, 2001) under low serum
conditions resulted in cultures comprising ∼80% definitive
endoderm cells (D'Amour et al., 2005). Suppression of PI3K
activity and reduction of insulin/insulin-like growth factor
signaling proved critical for efficient definitive endoderm
formation, as it induces the cells to go through a mesendo-
derm stage in response to Activin/Nodal signals (McLean et
al., 2007). The efficiency of definitive endoderm generation
improved further with exposure of hESCs to a combination of
Activin A and Wnt3a in the complete absence of serum on the
first day, followed by two days in medium supplemented
with Activin A and 0.2% serum (D'Amour et al., 2006). These
differentiation methods (D'Amour et al., 2005; McLean et al.,
2007) result in transient upregulation of the mesendoderm
markers Brachyury T (Kubo et al., 2004), Foxc1, and Mixl1
(Pearce and Evans, 1999; Hart et al., 2002), and sustained
expression of the definitive endoderm markers Cer1, Cxcr4
(Nair and Schilling, 2008), Foxa2 (Sasaki and Hogan, 1993;
Monaghan et al., 1993), Gata4 (Narita et al., 1997) and 6, Gsc
(Blum et al., 1992), Hhex (Bort et al., 2004), and Sox17
(Kanai-Azuma et al., 2002) from day 3 after the onset of
differentiation (Liu et al., 2007).
Recently, this Activin A-based differentiation strategy has
also been applied to hESCs grown on human feeder cells
(Zhou et al., 2008), and with a lower efficiency under feeder-
free conditions in the absence of any xeno factors (Zhou et
al., 2008; King et al., 2008). Furthermore, wortmannin
improves the yield of definitive endoderm cells through
inhibition of PI3K activity (Zhang et al., 2009), and the
replacement of Activin A with Activin B further increases the
number of Pdx1-expressing cells in hESC-derived embryoid
bodies (Frandsen et al., 2007). Recently, a screen for small
molecule inducers of endoderm identified two components,
termed IDE1 and IDE2, with efficiencies similar to that of
Activin A (Borowiak et al., 2009).
Exogenous expression of pancreas-associated
transcription factors
The timely expression of Pdx1 during early development of
endocrine cells, as well as its sustained presence in mature
islets (Jonsson et al., 1994; Offield et al., 1996), has been
difficult to accomplish in vitro. An inducible system to
control the expression of a Pdx1-VP16 fusion protein (Kanetoet al., 2005) stimulated the differentiation of hESC-derived
definitive endoderm cells into endocrine pancreas-like cells
(Bernardo et al., 2008). However, their endocrine-like
identity was based primarily on mRNA analyses and limited
immunocytochemistry; C-peptide expression was not dem-
onstrated, and no functional studies were conducted.
Constitutive overexpression of Pax4 (Smith et al., 2003)
also enhanced the differentiation of hESCs into cells when
subjected to an embryoid body-based procedure, as
evidenced by upregulated expression of endogenous β-cell-
associated transcripts (Liew et al., 2008). The differentiated
cells were enriched in Pdx1 and insulin transcripts, and
stained positive for pro-insulin, indicating de novo synthesis.
Although these cells released marginal levels of C-peptide on
exposure to the insulin secretagogue tolbutamide (Sturgess
et al., 1986), they did not respond to glucose stimuli,
indicating that the cells had not gained characteristics of
mature β-cells (Liew et al., 2008).
Directed differentiation into insulin-producing cells
Mimicking the environmental conditions during pancreagen-
esis in vivo by the successive exposure of pluripotent hESCs
to different growth factors and other signaling molecules in
vitro has proven most successful for generating hESC-derived
endocrine-like tissue (Table 1). Guiding differentiation of
hESCs into pancreatic cells by a stepwise process was
exploited shortly after achieving efficient formation of
definitive endoderm. Most of these multistage procedures
take 2 to 3 weeks (Fig. 2), a period much shorter than the in
vivo development of the human islet cells from the
pluripotent cells of the inner cell mass.
The exposure of hESCs to extracellular stimuli and
inhibitors in a consecutive manner has proven to be an
efficient method for generating pancreatic hormone-expres-
sing endocrine cells, even though the resulting insulin-
expressing cells still differ from mature β-cells (D'Amour et
al., 2006). After formation of definitive endoderm (D'Amour
et al., 2005), removal of Activin A allows the cells to adopt
gut endoderm-like characteristics. This can be enhanced by
the addition of FGF10 to stimulate proliferation (Hart et al.,
2002; Bhushan et al., 2001; Ye et al., 2005), KAAD-
cyclopamine to inhibit hedgehog signaling (Lau et al.,
2006), and indolactam V to activate PKC signaling (Chen et
al., 2009). Following this protocol, and growth in medium
supplemented with IGF1 and HGF, all five pancreatic
hormones are readily detected. The insulin content of
dithizone-stained cell clusters (Latif et al., 1988) generated
with this protocol exceeded the ∼2 pmol/μg DNA of human
fetal islets (Hayek and Beattie, 1997; Demeterco et al.,
2000) by 7- to 100-fold, thereby approximating levels of
mature islets, which range from 50 to 310 pmol/μg DNA.
However, many of the resulting endocrine cells express
multiple hormones simultaneously, thus resembling the
immature polyhormonal cells that arise during the primary
transition (Polak et al., 2000; De Krijger et al., 1992;
Teitelman et al., 1993).
This protocol, optimized primarily for the CyT203 hESC
cell line, also produced endocrine cells from five additional
cell lines (CyT25, CyT49, BG01, BG02, and BG03), albeit at
different efficiencies (D'Amour et al., 2006). Despite these
differences between hESC lines, Activin A induction of
Table 1 Studies reporting the directed differentiation of hESCs into insulin-producing cells.
Reference Cell lines Differentiation
conditions
Endocrine
hormones
human
C-peptide
Glucose responsive
insulin release
Transplant recipient Transplantation
site
Amelioration of
hyperglycemia
(D'Amour et al.,
2006)
CyT203 Adherent on low
density MEFs
GCG,INS, SST,
PPY, GHRL
Yes No n.a n.a n.d.
(Cho et al., 2008) SNUhES3 Adherent on low
density MEFs
GCG, INS Yes n.d. n.a n.a n.d.
(Jiang et al., 2007a) H1, H7, H9 Adherent on
Matrigel
GCG, INS, SST Yes No n.a n.a n.d.
(Zhang et al., 2009) H1, H9 Adherent on
Matrigel
INS, SST Yes In vitro n.a. n.a. n.d.
(Eshpeter et al., 2008) H1 Adherent on
Matrigel
GCG, INS, SST Yes In vitro
(moderate)
C57BL6 Rag-1/-1 mice Kidney capsule No
(Phillips et al., 2007) HES-1, HES-2,
HES-3, HES-4,
HUES-7, HUES-9
Suspension GCG, INS, SST Yes In vitro
(marginal)
Male SCID mice Intraperitoneal
injection
No
(Mao et al., 2009) PKU1.1 Adherent on
Gelatin
GCG, INS, SST, PPY Yes n.d. Male SCID mice Kidney capsule and
subcutaneous
Only when
fasting
(Shim et al., 2007) Miz-hES4, Miz-hES6 Suspension GCG, INS, SST Yes In vivo Male BALB/c nude mice Kidney capsule Yes
(Jiang et al., 2007b) H1, H9 Adherent on
Matrigel
GCG, INS, SST Yes In vitro (marginal)
and in vivo
Male BALB/c nude mice Kidney capsule Yes
(Kroon et al., 2008) CyT49 Adherent on low
density MEFs
GCG, INS, SST,
PPY, GHRL
Yes In vivo Male SCID-Beige mice Epididymal fat pad Yes
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Figure 2 Time lines of the various multistep procedures to induce differentiation of hESCs into insulin-secreting cells. Abbreviations: ActA, Activin A; bFGF, basic fibroblast growth
factor; BMP4, bone morphogenetic protein 4; CM, conditioned medium; DAPT, γ-secretase inhibitor; EGF, epidermal growth factor; FBS, fetal bovine serum; FGF10, fibroblast growth
factor 10; HGF, hepatocyte growth factor; IGF1, insulin-like growth factor 1; IGF2, insulin-like growth factor 2; KGF, keratinocyte growth factor; MEFs, mouse embryonic fibroblast
feeders; Nic, nicotinamide; RA, all-trans retinoic acid.
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81Derivation of insulin-producing cells from human embryonic stem cellsdefinitive endoderm has subsequently been applied in
multiple studies with a variety of hESC lines cultured and
derived under diverse conditions (Kroon et al., 2008; Jiang et
al., 2007a,b; Phillips et al., 2007; Shim et al., 2007; Cho et
al., 2008).
The five-stage protocol was slightly modified for the hESC
line SNUhES3 with the inclusion of nicotinamide and β-
cellulin during the last two stages, which resulted in
sustained expression of Pdx1 (Cho et al., 2008). In
combination with Activin A, β-cellulin promotes the conver-
sion of amylase-secreting exocrine pancreatic cells into
insulin-producing cells (Mashima et al., 1996), and stimu-
lates β-cell regeneration when injected into pancreatecto-
mized rats (Li et al., 2001). In addition to inducing endocrine
differentiation of human fetal pancreatic cells in culture
(Otonkoski et al., 1993), nicotinamide increases the mitotic
index of β-cells after pancreatectomy (Sugiyama et al.,
1991). However, even though the resulting endocrine cells
retain Pdx1 expression, the insulin concentration in the
culture medium after stimulation with various secretagogues
does not increase significantly in the cells derived with use of
nicotinamide and β-cellulin (Cho et al., 2008).
A combination of Activin A and the histone deacetylase
inhibitor Na-butyrate (Candido et al., 1978) at the first stage
increases the expression levels of the endoderm markers
Sox17, Foxa2, and Hnf4a (Jiang et al., 2007a). Furthermore,
addition of Noggin during the second and third stage of the
protocol enhances differentiation of definitive endoderm
into pancreatic endoderm (Kroon et al., 2008; Zhang et al.,
2009; Jiang et al., 2007a), possibly by antagonizing BMP
signaling (Winnier et al., 1995; Solloway and Robertson,
1999), thus excluding a hepatic fate (Rossi et al., 2001).
Under these growth conditions, islet-like clusters can be
generated that contain glucagon-, somatostatin-, and
insulin-producing cells, the latter of which increase C-
peptide release 3.5-fold on glucose stimulation (Jiang et
al., 2007a). Although transplantation of these clusters under
the kidney capsule of streptozotocin-induced diabetic mice
did not reduce blood glucose levels significantly, human C-
peptide could be detected in serum after an oral glucose
bolus (Eshpeter et al., 2008).
EGF treatment can increase the number of Pdx1-positive
cells in vitro to nearly 40%, suggesting that these cells might
function as an expandable population of progenitor cells for
generating the large numbers of endocrine cells required for
transplantations (Zhang et al., 2009). Pancreatic endocrine
cells that arise at the final stage of this differentiation
procedure do not coexpress insulin with glucagon or
somatostatin and give a 2-fold increase in insulin release
on glucose stimulation, but have not been tested for
amelioration of hyperglycemia in vivo (Zhang et al., 2009).
Interestingly, human iPS cells in place of hESCs give similar
results. Furthermore, the small molecule indolactam V can
produce similar effects as those observed for EGF, but only
when combined with FGF10 (Chen et al., 2009).
As noted before, growing hESCs as aggregates in suspen-
sion results in their spontaneous differentiation into various
lineages, including the extraembryonic lineages such as
visceral endoderm (Mitsui et al., 2003). BMP4 also promotes
differentiation of hESCs into extraembryonic endoderm
(Pera et al., 2004). In contrast, growth on Matrigel
suppresses visceral endoderm formation in embryoid bodies(Rust et al., 2006). When combined with Activin A and
Matrigel, BMP4 induces expression of Sox17 and Foxa2 in
hESC-derived embryoid bodies (Phillips et al., 2007).
Although the precise role of BMP4 in this process is not
clear it has been argued that this represents differentiation
of hESCs into definitive endoderm rather than the extraem-
bryonic lineage. Irrespectively, the resulting islet-like
clusters studied at the end of this differentiation protocol
contained 5–20% Pdx1-positive cells, and these clusters
secreted C-peptide in response to glucose stimulation, albeit
at very low levels.
Glucose-responsive insulin-producing cells that
ameliorate hyperglycemia
Although several of the studies discussed above describe
increased secretion of insulin and C-peptide by hESC-derived
pancreatic endocrine cells on glucose stimulation in vitro,
none produced cells capable of restoring euglycemia in
diabetic animal models in vivo (e.g., streptozotocin-treated
mice). Recently, several independent groups used distinct
differentiation conditions to develop hESC-derived insulin-
secreting cells that were glucose responsive in vivo (Fig. 2)
(Kroon et al., 2008; Jiang et al., 2007b; Shim et al., 2007).
The first two of these studies were published almost
simultaneously, one of which relied on the formation of
embryoid bodies at the onset of the differentiation proce-
dure (Shim et al., 2007), whereas the other applied an
aggregation step at the very end of the protocol (Jiang et al.,
2007b). Both differentiation methodologies included Activin
A at the start to generate definitive endoderm (De
Caestecker, 2001), and retinoic acid during the second
stage to stimulate the formation of pancreatic endoderm, as
determined by the expression of specific transcription
factors, among which were Foxa2, Sox17, Pdx1, Gata4, and
Mnx1.
Though only one of the two studies showed a meager 2-
fold increase in insulin secretion by their differentiated cells
on glucose stimulation in vitro (Jiang et al., 2007b), both
groups transplanted their cell clusters under the renal
capsule of streptozotocin-treated diabetic mice. Surprising-
ly, this resulted in a significant reversal of the hyperglyce-
mic state in 30% (Jiang et al., 2007b) or all of the recipients
within one week, and was associated with a gain in weight
(Shim et al., 2007), suggesting that the insulin-producing
cells in the grafts had matured into functional β-cell-like
cells. This conclusion was further supported by the
immediate increase in blood glucose levels on removal of
the transplantation site after 4 (Shim et al., 2007) or 6
weeks (Jiang et al., 2007b). Immunofluorescence micro-
scopic analysis indicated that many human cells in the grafts
coexpressed Pdx1 and insulin (Shim et al., 2007) or C-
peptide (Jiang et al., 2007b), though some cells resembled
more immature endocrine cells, as they were immunoreac-
tive for both insulin and glucagon (Shim et al., 2007).
Interestingly, no teratomas were found at 4 weeks (Shim et
al., 2007) or even 3 months (Jiang et al., 2007b) when the
studies were concluded, suggesting that all pluripotent cells
had either differentiated into nonproliferative cells, or had
not survived.
The finding that only 6 out of 19 of the recipient mice
sustained long-term restoration of euglycemia was ascribed to
82 D. Van Hoof et al.the physiological difference between human and mouse, and
the impurity of the grafts, which may account for poor or
delayed revascularization after implantation (Jiang et al.,
2007b). However, the most remarkable finding was that,
although transplantation of these islet-like structures rapidly
reverseddiabetes, noC-peptide could bedetected in the serum
at fasting conditions or after feeding, yet cells containing C-
peptide were present in the grafts (Jiang et al., 2007b). This
dichotomy may be explained by the limited sensitivity of the
method used to measure serum C-peptide levels.
Recently, a new strategy was adopted to generate
glucose-responsive insulin-producing cells (Kroon et al.,
2008). The five-stage protocol developed previously
(D'Amour et al., 2006) was improved empirically as based
on expression levels of pancreatic progenitor and endocrine
cell markers. Furthermore, the protocol was limited to the
first four stages, at the end of which hESCs have differen-
tiated into pancreatic endoderm-like tissue that contains
few hormone-expressing cells (Kroon et al., 2008). This
tissue, resembling the 6- to 9-week-old human pancreas, was
cut into small chunks and wrapped in Gelfoam overlaid with
Matrigel before transplantation into the epididymal fat pads
of immune-compromised normoglycemic mice (Figs. 3A–C)
to allow further development in vivo. In contrast to the
studies described above, these grafts become fully respon-
sive to glucose 3 months posttransplantation. Serum human
C-peptide levels in mice with these hESC-derived grafts were
∼660 pM at fasting, and∼2180 pM on intraperitoneal glucose
administration, approximating that of mice with human islet
implants (∼330 pM at fasting, and ∼3130 pM after glucose
stimulation). Secretion of mature human insulin showed a
similar pattern and was similar to that found for mice that
had received human islets (Gaber et al., 2004); (Kroon et al.,
2008).
Immunohistochemical analysis showed that the hESC-
derived grafts exhibited features associated typically withFigure 3 Transplantation of hESC-derived pancreatic endoderm in
(B) Pancreatic endoderm layered on the epididymal fat pad. (C) Ep
hESC-derived pancreatic endoderm graft 377 days postimplantatio
(green); scale bar, 100 μm.mature pancreatic islets, including their overall structural
organization, and the mutually exclusive expression of all
endocrine hormones (Kroon et al., 2008). Furthermore, the
transcription factors Pdx1, Nkx6.1, and MafA as well as islet
amyloid polypeptide were expressed in insulin-positive cells,
whereas glucagon-positive cells expressed the α-cell-specif-
ic transcription factor Arx, but were devoid of islet amyloid
polypeptide and MafA. In addition to releasing human C-
peptide and insulin in response to a glucose challenge, the
grafts protected these mice from becoming diabetic after
streptozotocin treatment. When the grafts were removed
2.5 to 3 months later, blood glucose levels increased
promptly to hyperglycemic levels, which further corrobo-
rates that the hESC-derived endocrine cells had matured and
had become fully functional in vivo. Interestingly, these
insulin-expressing implants remained viable for more than a
year, while sustaining expression of Pdx1 (Fig. 3D), which is
critical for the proper functioning of β-cells, but had not
been reported for in vitro-derived grafts before.Conclusions and prospectives
Formation of the pancreas, and the clusters of endocrine
cells therein, depends on growth factor-induced signaling as
well as the interaction with neighboring cells and tissues that
are tightly regulated in timely manner in vivo (Murtaugh,
2007). Mimicking this complex developmental process to
drive the differentiation of hESCs into β-cell-like cells in
vitro has proven challenging, but several important break-
throughs have been published over the past few years.
In contrast to the other primary germ layers, endoderm
proved particularly difficult to produce, until the use of
Activin A yielded the formation of definitive endoderm from
hESCs with efficiencies exceeding 80% (D'Amour et al., 2005);
(D'Amour et al., 2006). Since then, the most successfulto the epididymal fat pad. (A) The epididymal fat pad exposed.
ididymal fat pad wrapped around the pancreatic endoderm. (D)
n, stained with immunofluorescence for Pdx1 (red) and insulin
83Derivation of insulin-producing cells from human embryonic stem cellsmultistep protocols commonly include Activin A during the
initial stage, but vary widely at the subsequent stages. Some
incorporate an aggregation step through suspension growth
to form multicellular clusters (Phillips et al., 2007; Shim et
al., 2007). However, the assembly process itself may initiate
spontaneous differentiation into undesired types of cells, and
the clusters might also reduce the diffusion efficiency of
growth factors and small molecules, thus forming a concen-
tration gradient from the periphery to the core of the cluster.
An aggregation stepmight contribute to the generation of the
classical islet-like shape, but it is unclear whether the insulin-
producing cells have to reside in clusters for their proper
functioning and survival after transplantation.
Even though independent groups have shown repeatedly
that insulin-producing cells can be derived from hESCs in
vitro, none of these end-stage products responded ade-
quately to exogenous glucose stimuli to meet the require-
ments for surrogate β-cells. Based on the observed
expression of multiple endocrine hormones per cell, it has
been argued that these cells may represent immature
endocrine cells that might develop eventually into fully
functional glucose-responsive cells.
One successful approach to the treatment of experimen-
tal diabetes with hESC-derived cells did not use fully
differentiated insulin-producing cells, but a heterogeneous
population of cells containing pancreatic endoderm-like
tissue (Kroon et al., 2008). The additional weeks of
development in vivo that were required before endocrine
cells fully differentiated and normoglycemia was achieved in
these grafts of pancreatic endoderm suggest that the final
differentiation process may take longer than allowed for the
in vitro protocols. Thus final maturation may simply depend
on time.
Alternatively, other undefined factors that are difficult to
reproduce in vitro, such as vascularization, and the
interaction with adjacent tissues, may contribute to the
final steps of maturation of functional endocrine cells. The
source of such signals remains unknown, although they do not
appear to depend on the normal pancreatic location, since
the epididymal fat pad appeared apt at providing those
signals. It also remains possible that other undefined hESC-
derived cells included with the engrafted pancreatic
endoderm tissue have assisted the differentiation of pro-
genitors into mature endocrine cells. Further progress on
defining these signals may aid efforts to complete the final
differentiation steps of mature β-cells in vitro.
The different strategies developed to derive β-cell-like
cells from hESCs described thus far have yielded relatively
small numbers of pancreatic endocrine cells, and the
heterogeneous nature of the resulting cell populations
could prove problematic. We do not know whether cotrans-
planting such nonendocrine cells or undifferentiated cells
represents a risk to patients. Interestingly, transplantation
of a mixed population of human cells into mice showed a
strong bias toward the eventual formation of endocrine cells
(Kroon et al., 2008), suggesting that the heterogeneous
grafts experienced either a positive selection (i.e., a
preference for endocrine cells to proliferate and differenti-
ate) or a negative selection (i.e., a higher death rate of
nonendocrine cells). However, teratomas can arise in
recipient mice that receive unpurified hESC grafts, indicat-
ing that the inclusion of a purification step prior totransplantation is desired to dispose of potentially hazardous
mitotically active cells.
Despite all the hurdles that need to be taken before hESC-
derived differentiated cells reach the clinics, stem cell
research has proven its potential repeatedly in animal model
systems. Moreover, the recent approval of the world's first
clinical trial involving hESC-derived oligodendrocyte progen-
itor cells that had been shown to remyelinate and restore
locomotion in rats after spinal cord injury (Keirstead et al.,
2005) will pave the way for future trials. Although as of now,
only the symptoms of diabetes can be treated, the
investigations discussed here suggest that a definitive cure
for diabetes has come closer.
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